Biocon Biologics secures multiple market access agreements in US for Yesintek

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Multiple formularies, including Express Scripts, Cigna, and UnitedHealthcare, will include Yesintek starting in 2025. This approval expands affordable treatment options for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AlgfezL
via IFTTT